MaxCyte, Inc. (MXCT) cash flow statement
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3062% below fair value
$1.28+0.03 (+2.40%)
Close on Nov 19, 2026Market cap $132.10MP/E –Yield –
MaxCyte, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.2%
- Operating margin
- -134.6%
- Net margin
- -114.8%
- Return on equity, FY2025
- -23.6%
Financial strength
- Current ratio
- 12.26
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 152.0%
Valuation
- P/E ratio
- –
- Price to sales
- 4.25
- Price to book
- 0.83
- Dividend yield
- –
See a number that looks wrong?